Pure Bioscience Inc (PURE) financial statements (2020 and earlier)

Company profile

Business Address 9669 HERMOSA AVENUE
RANCHO CUCAMONGA, CA 91730
State of Incorp. DE
Fiscal Year End July 31
SIC 289 - Miscellaneous Chemical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2020
TTM
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
7/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0012510
Cash and cash equivalents0012510
Receivables0000000
Inventory, net of allowances, customer advances and progress billings0000000
Inventory0000000
Prepaid expense0000000
Other undisclosed current assets000000 
Total current assets:1112620
Noncurrent Assets
Property, plant and equipment0001000
Intangible assets, net (including goodwill)011111 
Intangible assets, net (excluding goodwill)011111 
Other undisclosed noncurrent assets      1
Total noncurrent assets:1111111
TOTAL ASSETS:1234832
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111111
Accounts payable1110011
Accrued liabilities0000000
Debt  1   0
Derivative instruments and hedges, liabilities   2200
Restructuring reserve   000 
Total current liabilities:1113312
Noncurrent Liabilities
Liabilities, other than long-term debt 000000
Deferred revenue and credits0000
Deferred rent credit 00
Total noncurrent liabilities: 000000
Total liabilities:1113312
Stockholders' equity
Stockholders' equity attributable to parent1111520
Common stock1111100
Additional paid in capital1251241181101089181
Accumulated deficit(125)(123)(117)(109)(103)(89)(81)
Total stockholders' equity:1111520
TOTAL LIABILITIES AND EQUITY:1234832

Income statement (P&L) ($ in millions)

1/31/2020
TTM
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
7/31/2014
Revenues2222111
Revenue, net2111
Cost of revenue
(Cost of Goods and Services Sold)
(1)(1)(1)(0)(0)(0)(0)
Gross profit:1112100
Operating expenses(5)(7)(9)(8)(8)(8)(12)
Other undisclosed operating income1110000
Operating loss:(4)(6)(7)(6)(7)(8)(12)
Nonoperating income (expense)(1)(1)(0)(0)(7)01
Investment income, nonoperating  0(0)(5)0(0)
Other nonoperating income0000000
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Loss from continuing operations before income taxes:(4)(7)(7)(6)(14)(8)(11)
Income tax expense     (0) 
Net loss:(4)(7)(7)(6)(14)(8)(11)
Other undisclosed net income attributable to parent0000000
Net loss available to common stockholders, diluted:(4)(7)(7)(6)(14)(8)(11)

Comprehensive Income ($ in millions)

1/31/2020
TTM
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
7/31/2014
Net loss:(4)(7)(7)(6)(14)(8)(11)
Comprehensive loss, net of tax, attributable to parent:(4)(7)(7)(6)(14)(8)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: